Lexeo Therapeutics (LXEO) Free Cash Flow (2022 - 2026)
Lexeo Therapeutics (LXEO) reported Free Cash Flow of -$21.2 million for Q1 2026, up 2.47% on a YoY basis from -$20.7 million in Q1 2025, and down 5.48% sequentially from -$20.1 million in Q4 2025.
Lexeo Therapeutics (LXEO) Free Cash Flow (2022 - 2026) Analysis & Trends
Lexeo Therapeutics (LXEO) has 5 years of Free Cash Flow data on file, last reported at -$21.2 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow rose 2.47% year-over-year to -$21.2 million; the trailing twelve-month figure through Mar 2026 stood at -$98.3 million (down 11.34% YoY), and the FY2025 full-year result was -$99.0 million, down 21.22% from the prior year.
- Free Cash Flow eased to -$21.2 million in Q1 2026, from -$20.1 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$13.2 million in Q2 2023 to a low of -$29.8 million in Q3 2025.
- A 5-year average of -$19.8 million and a median of -$19.2 million in 2023 frame the typical range for Free Cash Flow.
- Across the five-year window, Free Cash Flow plunged 101.55% in 2024 and increased 29.11% in 2025, its largest moves.
- Tracing LXEO's Free Cash Flow over 5 years: stood at -$16.5 million in 2022, then climbed by 14.94% to -$14.1 million in 2023, then plunged by 101.55% to -$28.3 million in 2024, then advanced by 29.11% to -$20.1 million in 2025, then fell by 5.48% to -$21.2 million in 2026.
- Business Quant data shows LXEO's Free Cash Flow at -$21.2 million in Q1 2026, -$20.1 million in Q4 2025, and -$29.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 158.09 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.95 Mn |
| 10 | Lexeo Therapeutics | 382.38 Mn | 382.38 Mn | - | -21.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.18 Mn |
| Mar 31, 2026 | -21.18 Mn |
| Dec 31, 2025 | -20.08 Mn |
| Dec 31, 2025 | -20.08 Mn |
| Sep 30, 2025 | -29.84 Mn |
| Sep 30, 2025 | -29.84 Mn |
| Jun 30, 2025 | -27.22 Mn |
| Jun 30, 2025 | -27.22 Mn |
| Mar 31, 2025 | -21.72 Mn |
| Mar 31, 2025 | -21.72 Mn |
| Dec 31, 2024 | -28.33 Mn |
| Dec 31, 2024 | -28.33 Mn |
| Sep 30, 2024 | -17.89 Mn |
| Sep 30, 2024 | -17.89 Mn |
| Jun 30, 2024 | -20.37 Mn |
| Jun 30, 2024 | -20.37 Mn |
| Mar 31, 2024 | -15.05 Mn |
| Mar 31, 2024 | -15.05 Mn |
| Dec 31, 2023 | -14.05 Mn |
| Dec 31, 2023 | -14.05 Mn |